Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background Although metformin is increasingly being used in women with type 2 diabetes during pregnancy, little data exist on the benefits and harms of metformin use on pregnancy outcomes in these women. We aimed to investigate the effects of the addition of metformin to a standard regimen of insulin on neonatal morbidity and mortality in pregnant women with type 2 diabetes.Methods In this prospective, multicentre, international, randomised, parallel, double-masked, placebo-controlled trial, women with type 2 diabetes during pregnancy were randomly assigned from 25 centres in Canada and four in Australia to receive either metformin 1000 mg twice daily or placebo, added to insulin. Randomisation was done via a web-based computerised randomisation service and stratified by centre and pre-pregnancy BMI (<30 kg/m 2 or ≥30 kg/m 2) in a ratio of 1:1 using random block sizes of 4 and 6. Women were eligible if they had type 2 diabetes, were on insulin, had a singleton viable pregnancy, and were between 6 and 22 weeks plus 6 days' gestation. Participants were asked to check their fasting blood glucose level before the first meal of the day, before the last meal of the day, and 2 h after each meal. Insulin doses were adjusted aiming for identical glucose targets (fasting glucose <5·3 mmol/L [95 mg/dL], 2-h postprandial glucose <6·7 mmol/L [120 mg/dL]). Study visits were done monthly and patients were seen every 1-4 weeks as was needed for standard clinical care. At study visits blood pressure and bodyweight were measured; patients were asked about tolerance to their pills, any hospitalisations, insulin doses, and severe hypoglycaemia events; and glucometer readings were downloaded to the central coordinating centre. Participants, caregivers, and outcome assessors were masked to the intervention. The primary outcome was a composite of fetal and neonatal outcomes, for which we calculated the relative risk and 95% CI between groups, stratifying by site and BMI using a log-binomial regression model with an intention-to-treat analysis. Secondary outcomes included several relevant maternal and neonatal outcomes. The trial was registered with ClinicalTrials.gov, NCT01353391.Findings Between May 25, 2011, and Oct 11, 2018, we randomly assigned 502 women, 253 (50%) to metformin and 249 (50%) to placebo. Complete data were available for 233 (92%) participants in the metformin group and 240 (96%) in the placebo group for the primary outcome. We found no significant difference in the primary composite neonatal outcome between the two groups (40% vs 40%; p=0·86; relative risk [RR] 1·02 [0·83 to 1·26]). Compared with women in the placebo group, metformin-treated women achieved better glycaemic control (HbA 1c at 34 weeks' gestation 41·0 mmol/mol [SD 8·5] vs 43·2 mmol/mol [-10]; 5·90% vs 6·10%; p=0·015; mean glucose 6·05 [0·93] vs 6·27 [0·90]; difference -0·2 [-0·4 to 0·0]), required less insulin (1·1 units per kg per day vs 1·5 units per kg per day; difference -0·4 [95% CI -0·5 to -0·2]; p<0·0001), gained less weight (7·2 kg vs 9·0 kg; difference -1·8 [-2·7 to -0·9]; p<0·0001) and had fewer caesarean births (125 [53%] of 234 in the metformin group vs 148 [63%] of 236 in the placebo group; relative risk [RR] 0·85 [95% CI 0·73 to 0·99]; p=0·031). We found no significant difference between the groups in hypertensive disorders (55 [23%] in the metformin group vs 56 [23%] in the placebo group; p=0·93; RR 0·99 [0·72 to 1·35]). Compared with those in the placebo group, metformin-exposed infants weighed less (mean birthweight 3156 g [SD 742] vs 3375 g [742]; difference -218 [-353 to -82]; p=0·002), fewer were above the 97th centile for birthweight (20 [9%] in the metformin group vs 34 [15%] in the placebo group; RR 0·58 [0·34 to 0·97]; p=0·041), fewer weighed 4000 g or more at birth (28 [12%] in the metformin group vs 44 [19%] in the placebo group; RR 0·65 [0·43 to 0·99]; p=0·046), and metformin-exposed infants had reduced adiposity measures (mean sum of skinfolds 16·0 mm [SD 5·0] vs 17·4 [6·2] mm; difference -1·41 [-2·6 to -0·2]; p=0·024; mean neonatal fat mass 13·2 [SD 6·2] vs 14·6 [5·0]; p=0·017). 30 (13%) infants in the metformin group and 15 (7%) in the placebo group were small for gestational age (RR 1·96 [1·10 to 3·64]; p=0·026). We found no significant difference in the cord c-peptide between groups (673 pmol/L [435] in the metformin group vs 758 pmol/L [595] in the placebo group; p=0·10; ratio of means 0·88 [0·72 to 1·02]). The most common adverse event reported was gastrointestinal (38 events in the metformin group and 38 events in the placebo group).Interpretation We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants. Understanding the implications of these effects on infants will be important to properly advise patients who are contemplating the use of metformin during pregnancy.Funding Canadian Institutes of Health Research, Lunenfeld-Tanenbaum Research Institute, University of Toronto.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“An RCT of metformin added to insulin for the treatment of type 2 diabetes found less maternal weight gain and fewer cesarean births.”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [112]
The cited source says what the claim attributes to it.
In the citing paper
“There were fewer macrosomic neonates, but there was a doubling of small-for-gestational-age neonates (112).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barker, D. J. P., Hales, C. N., Fall, C. H. D., Osmond, C., Phipps, K., & Clark, P. M. S. (1993) · Diabetologia · doi:10.1007/bf00399095 · Cited by 2,468
A New and Improved Population-Based Canadian Reference for Birth Weight for Gestational Age
Kramer, M. S., Platt, R. W., Wen, S. W., Joseph, K. S., Allen, A., Abrahamowicz, M., Blondel, B., Bréart, G., & for the Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System (2001) · Pediatrics · doi:10.1542/peds.108.2.e35 · Cited by 1,524
Measurement of socioeconomic status in health disparities research.
Shavers, V. L. (2007) · PubMed · doi:10.13016/avw3-9cvx · Cited by 956
Type 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824
Feig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
Self-citationSantos, S., Voerman, E., Amiano, P., Barros, H., Beilin, L., Bergström, A., Charles, M., Chatzi, L., Chevrier, C., Chrousos, G., et al. (2019) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15661 · Cited by 591
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
Thompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Self-citationLanger, O., Levy, J., Brustman, L., Anyaegbunam, A., Merkatz, R., & Divon, M. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90371-2 · Cited by 376
Feig, D. S., Hwee, J., Shah, B. R., Booth, G. L., Bierman, A. S., & Lipscombe, L. L. (2014) · Diabetes Care · doi:10.2337/dc13-2717 · Cited by 346
Self-citation
Research works printed but not linked: 2
- Rasmussen KM, Yaktine AL, Institute of Medicine (U.S.). Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight gain during pregnancy : reexamining the guidelines. Washington, DC: National Academies Press; 2009.
- Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2019. · DOI · Paper page
Cited by
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Gestational diabetes mellitus - A metabolic and reproductive disorder
Choudhury, A. A., & Devi Rajeswari, V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112183 · Cited by 442
Epidemiology and management of gestational diabetes
Sweeting, A., Hannah, W., Backman, H., Catalano, P., Feghali, M., Herman, W. H., Hivert, M.-F., Immanuel, J., Meek, C., Oppermann, M. L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00825-0 · Cited by 431
Self-citationMurphy, H. R., Howgate, C., O'Keefe, J., Myers, J., Morgan, M., Coleman, M. A., Jolly, M., Valabhji, J., Scott, E. M., Knighton, P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30406-x · Cited by 346
Self-citation
Metadata
- Authors
- Feig, D. S., Donovan, L. E., Zinman, B., Sanchez, J. J., Asztalos, E., Ryan, E. A., Fantus, I. G., Hutton, E., Armson, A. B., Lipscombe, L. L., Simmons, D., Barrett, J. F. R., Karanicolas, P. J., Tobin, S., McIntyre, H. D., Tian, S. Y., Tomlinson, G., Murphy, K. E., Feig, D., Donat, D., Gandhi, S., Cleave, B., Zhou, V., Viguiliouk, E., Fong, D., Strom, M., Deans, M., Kamath, A., Godbout, A., Weber, F., Mahone, M., Wo, B. L., Bedard, M.-J., Robinson, M., Daigle, S., Leblanc, S., Ludwig, S., Pockett, S., Slater, L., Donovan, L., Oldford, C., Young, C., Virtanen, H., Lodha, A., Cooper, S., Yamamoto, J., Gougeon, C., Verhesen, C., Zahedi, A., Taha, N., Turner, M., Neculau, M., Robb, C., Szwiega, K., Lee, G., Rey, E., Perreault, S., Coolen, J., Armson, A. B., Ransom, T., Dias, R., Slaunwhite, J., Baxendale, D., Fanning, C., Halperin, I., Gale, V., Kader, T., Hirsimaki, H., Long, H., Lambert, J., Castonguay, A., Chalifoux, S., McManus, R., Watson, M., Powell, A.-M., Sultana, M., ArthurHayward, V., Marin, M., Cauchi, L., MacBean, L., Keely, E., Malcolm, J., Clark, H., Karovitch, A., Belanger, H., Champagne, J., Schutt, K., Sloan, J., Mitchell, J., Favreau, C., O'Shea, E., McGuire, D., Peng, M., St Omer, D., Lee, J., Klinke, J., Young, S., Lee, J., Barts, A., Carr, F., Subrt, P., Miller, D., Coles, K., Capes, S., Smushkin, G., Phillips, R., Fergusson, C., Lacerte, S., Houlden, R., Breen, A., Stone-Hope, B., Ryan, E. A., Kwong, S., Rylance, H., Khurana, R., McNab, T., Beauchamp, S., Weisnagel, S. J., D'Amours, M., Allen, C., Dubé, M.-C., Julien, V.-È., Lambert, C., Bourbonniere, M.-C., Rheaume, L., Bouchard, M., Carson, G., Williams, S., Wolfs, M., Berger, H., Cheng, A., Ray, J., Hanna, A., De Souza, L., Berndl, L., Meltzer, S., Garfield, N., El-Messidi, A., Bastien, L., Segal, S., Thompson, D., Lim, K., Kong, J., Thompson, S., Orr, C., Galway, B., Parsons, M., Rideout, K., Rowe, B., Crane, J., Andrews, W., Joyce, C., Newstead-Angel, J., Brandt, J., Meier, S., Laurie, J., McIntyre, D., Liley, H., Fox, Barrett, H., Maguire, F., Nerdal-Bussell, M., Nie, W., Bergan, C., Cavallaro, B., Tremellen, A., Cook, A., Simmons, D., Rajagopal, R., Vizza, L., Mattick, M., Bishop, C., Nema, J., Kludas, R., McLean, M., Hendon, S., Sigmund, A., Wong, V., Lata, P., Russell, H., Singh, R., Zinman, B., Asztalos, E., Fantus, G. I., Lipscombe, L. L., Barrett, J., Tomlinson, G., Murphy, K., McMurray, K., Karanicolas, P., Murphy, H., Sanchez, J., Klein, G., Tian, S., Tobin, S., & Mangoff, K.
- Affiliations
- Mount Sinai Hospital (CA)
- McMaster University (CA)
- Sunnybrook Hospital (CA)
- University of Toronto (CA)
- The University of Queensland (AU)
- University Health Network (CA)
- Sunnybrook Health Science Centre (CA)
- ORCID
- Hutton, Eileen
- Tian, Simon Yu
- Gandhi, Shital
- Virtanen, Heidi
- Lodha, Abhay
- Yamamoto, Jennifer
- Lee, Grace
- Coolen, Jillian
- Halperin, Ilana
- Watson, Margaret
- Malcolm, Janine
- Clark, Heather
- Subrt, Peter
- Miller, David
- Smushkin, Galina
- Houlden, Robyn
- Khurana, Rshmi
- McNab, Tammy
- Weisnagel, S John
- Dubé, Marie-Christine
- Berger, Howard
- Cheng, Alice
- Ray, Joel
- Hanna, Amir
- Garfield, Natasha
- Laurie, Josephine
- Liley, Helen
- Barrett, Helen
- Tremellen, Anne
- Vizza, Lisa
- McLean, Mark
- Wong, Vincent
- Russell, Hamish
- Murphy, Helen
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 8
- Issue
- 10
- Pages
- 834-844
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3085210273
- Cited by
- 234
- References
- 33
- Citations by year
- 2026: 25 · 2025: 53 · 2024: 48 · 2023: 41 · 2022: 35 · 2021: 30 · 2020: 2
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Update notices
- erratum (2020-11-01)
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion, cc-by-nc-nd)
- Funders
- Medtronic
- Canadian Institutes of Health Research
- Novo Nordisk
- Department of Medicine, University of Toronto
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes in pregnancy, insulin therapy, neonatal outcomes, fetal outcomes, neonatal morbidity, neonatal mortality, pre-pregnancy body mass index, gestational diabetes mellitus, glycemic control, neonatal intensive care admission, neonatal sepsis, neonatal respiratory distress syndrome, neonatal jaundice
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, International Agencies, Metformin, Middle Aged, Pregnancy, Pregnancy Outcome, Prospective Studies, Biomarkers, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30310-7
- The paper
- Feig, D. S., Donovan, L. E., Zinman, B., Sanchez, J. J., Asztalos, E., Ryan, E. A., Fantus, I. G., Hutton, E., Armson, A. B., Lipscombe, L. L., Simmons, D., Barrett, J. F. R., Karanicolas, P. J., Tobin, S., McIntyre, H. D., Tian, S. Y., Tomlinson, G., Murphy, K. E., Feig, D., . . . Mangoff, K. (2020). Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30310-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.